Hydrocodone rescheduling limits access while raising costs
Survey respondents say pain medication comes at higher cost, including stigmatization. Read More »
Survey respondents say pain medication comes at higher cost, including stigmatization. Read More »
Cumberland Pharmaceuticals said on Wednesday that it is entering a Phase II development program for Boxaban (ifetroban), an oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD). Read More »
Amgen said on Wednesday that its Biologics License Application (BLA) for talimogene laherparepvec will be reviewed by the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) and the Cellular, Tissue and Gene Therapies Advisory Committee. Read More »
Amgen’s Phase 3 study assessing the safety and effectiveness of biosimilar candidate ABP 501 versus Humira in patients with moderate to sever rheumatoid arthritis revealed positive results. Read More »